Zhongsheng Pharmaceutical: Acquired 12.06% equity stake in its controlling subsidiary Zhongsheng Ruichuang.

Zhongsheng Pharmaceutical announced that the company held the fifth meeting of the ninth board of directors on August 17, 2026, during which relevant proposals were reviewed and approved. The company agreed to use its own funds of $28.2621 million to acquire a total of 12.06% of the shares held by Southern Orchard Limited, Snow Owl, LLC, and BioTrack Capital Fund I, LP in the subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. After the acquisition is completed, the company's shareholding in Zhongsheng Ruichuang will increase from 77.12% to 89.18%, and Zhongsheng Ruichuang will remain a controlled subsidiary of the company.